Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

I-Flow/HAPC

This article was originally published in The Gray Sheet

Executive Summary

Proposed sale price of I-Flow's InfuSystem infusion pump distribution subsidiary is reduced from $140 million to $100 million, plus a $12 million "earn out payment," under a memorandum of intent with purchaser HAPC, the firms announce Sept. 12. The price cut "reflects the realities of today's economic environment and the marketplace," explains I-Flow CEO Donald Earhart. The planned divestiture was announced last September to allow I-Flow to focus on its On-Q pain drug-delivery devices (1"The Gray Sheet" Oct. 9, 2006, p. 11)

You may also be interested in...



I-Flow’s Focus Is On-Q As It Drops Infusion Pump Distribution Unit

I-Flow's divestiture of its infusion pump distribution subsidiary InfuSystem for $140 mil. will help fund clinical trials and market share expansion efforts for its On-Q infusion system, the firm says

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel